Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure.
Reports of GLP–1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP–1RA–associated AKI among patients on anti-cancer drugs is unclear.
Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies.
The findings will be presented at ASN Kidney Week 2024 October 23– 27.
For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over 1 year.
Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs.
AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.
“Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during the administration of anti-cancer therapy,” said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health.
“We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.”
Source: American Society of Nephrology
